Cipro case 'poses threat to patent law'
The recent threat to override a patent of an anthrax drug in the US was a 'slippery slope' that could lead to other challenges to intellectual property rights, senior pharmaceutical industry
The recent threat to override a patent of an anthrax drug in the US was a 'slippery slope' that could lead to other challenges to intellectual property rights, senior pharmaceutical industry